For more information about the company or its products please contact us.
Founder Vascular Access Centers and co-founded Rex Medical with Whitfield Gardner in 1999 and directs R & D. Dr. McGuckin is
Director of the Philadelphia Vascular Institute located in Philadelphia, Pennsylvania. Dr. McGuckin's research interest include: Cardiovascular Systems, Endoscopy and Endosurgery, Peripheral Arterial Disease, Limb Salvage, Percutaneous Oncologic Therapy and therapy related to the End Stage Renal Disease population. He is currently researching recanalization of Central Venous Occlusion using RF ablation.
He holds 39 patents and has over 170 pending patents. Dr. McGuckin double majored in Mechanical Engineering and Pre-Medical from the University of Notre Dame in 1983. He received his M.D. from Hahnemann University in 1987, General Surgery in 1988, Masters Degree in Bioengineering at the University of Pennsylvania in 1990, Diagnostic Imaging in 1995, and completed his Fellowship in Interventional Radiology at the Hospital of the University of Pennsylvania in 1996.
Mr. Ferrari is a Co-Founder of De Novo Ventures which is one of the premier venture firms dedicated to Medical Devices and Bio-Technology. He has been a successful CEO of two publicly traded medical technology companies: Cardiovascular Imaging Systems, the first and leading developer of ultrasound imaging catheters and CardioThoracic Systems (CTC), the market leader in disposable instruments and systems for performing minimally invasive beating heart bypass surgery. Mr. Ferrari also Co-Founded the Medical Technology Group. Previously Mr. Ferrari held the positions of Executive Vice President and General Manager of ADAC Laboratories. In 1996 he founded Saratoga Ventures, a venture capital partnership that has provided seed financing to startup medical technology companies. Mr. Ferrari also serves as a faculty member of the Stanford Biodesign Emerging Entrepreneurs Forum, as well as a board member for the Stanford-Coulter Foundation for Translational Medicine. Mr. Ferrari is the recipient of the Mallinckrodt Award for Excellence in Medicine and has been a finalist for the Entrepreneur of the Year Award. Rich holds a BS degree from Ashland University and an MBA from the University of South Florida.
Bryan Grulke is a Partner at Volcano Capital. Previously, he was an Investment Associate. Prior to attending business school, he worked as a Senior Manager in the Corporate Strategy group at Philips International, where he focused on medical imaging and life sciences. He also previously worked as an Associate Consultant at Bain & Company. Mr. Grulke graduated from Harvard Business School and Duke University, summa cum laude with a BS degree in Economics
Lindsay L. Carter- joined Rex Medical as Vice President of Sales and Marketing/NBD in January, 2001 and was named President in 2009. Mr. Carter has over 25 years of experience in the interventional medical device industry including numerous leadership roles in Sales, Product Management, and Marketing Management positions with Boston Scientific. Prior to joining Boston Scientific, Carter held several Sales, Sales Management, and National Account Management positions with consumer products leader, Black & Decker Corporation. Mr. Carter received his M.B.A. from San Diego State University and B.S. from the University of California at San Diego.
Mr. Geist has over twenty-eight years of progressive experience in innovation, product development, manufacturing, quality assurance, and business management, with particular focus in single patient use medical devices. By combining individual effort and effective team and business leadership, he has achieved outstanding results throughout his career at Marquest Medical Products, Vital Signs, and GE Healthcare.
Dr. Lupa is currently Managing Director of High Country Venture, a venture firm in Boulder, Colorado that invests in early stage Life Science and IT companies. Dr. Lupa holds a B.S. from Northwestern University, an M. Phil. from the University of Sussex (England) in Biomedical Engineering and a PhD in Pharmacology from the University of Lund, Sweden. He conducted neuroscience research for fifteen years at institutions worldwide, including the University of Colorado and the University of California San Francisco. Dr. Lupa’s business experience came first in the brewing industry as founder, CEO and CFO of Tabernash Brewing Company, which was formed in 1993 and merged with Left Hand Brewing in 1998. Dr. Lupa then moved to private investment company Tango to focus on technology and Life Science investments. He has served as founding member of the Board of Directors of Taligen Therapeutics, Sierra Neuropharma, Oberon, DCS Surgical, and Theratogs, and was CFO of Taligen from inception of the company in 2004 until early 2008.
Robert is a serial entrepreneur and executive with over 25 years of experience in the healthcare and life science industries. Most recently he was President and CEO of ViroCyt, Inc. ViroCyt was founded to develop and commercialize rapid virus quantification methods which can be used to accelerate development of new vaccines and gene therapy applications. The company’s products were quickly adopted by leading pharmaceutical and biotech companies and ViroCyt was acquired by Sartorius AG in July 2016. Previously Robert was the Founder, President and CEO of Medivance, Inc., which he built into the worldwide leader in therapeutic hypothermia treatment for critically ill patients. Medivance was acquired by CR Bard in 2011 for $260M and Robert was named Entrepreneur of the Year for the Mountain/Desert Region by Ernst and Young. Prior to Medivance, Robert held senior management positions at Pfizer and Covidien. Robert earned a MBA from the University of Colorado, a MS in Microbiology from the University of Illinois and a BA in chemistry from Colorado College.